Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$84.75

-0.6 (-0.70%)

, AMGN

Amgen

$184.88

-0.72 (-0.39%)

08:03
09/28/17
09/28
08:03
09/28/17
08:03

AbbVie announces resolution of Humira patent disputes with Amgen

ABBV

AbbVie

$84.75

-0.6 (-0.70%)

AMGN

Amgen

$184.88

-0.72 (-0.39%)

  • 08

    Nov

  • 02

    Dec

  • 03

    Feb

  • 30

    Apr

  • 17

    May

ABBV AbbVie
$84.75

-0.6 (-0.70%)

09/25/17
UBSW
09/25/17
DOWNGRADE
Target $92
UBSW
Neutral
AbbVie downgraded to Neutral from Buy at UBS
UBS analyst Marc Goodman downgraded AbbVie to Neutral with the shares up 40% year-to-date. Investors this year have gained more confidence in the duration of Humira and in the company's pipeline, Goodman tells investors in a research note. After pushing out his assumption for U.S. biosimilar competition for Humira to 2022 from 2021, the analyst raised his price target for AbbVie shares to $92 from $79. Goodman, however, no longer sees enough upside to warrant a Buy rating. AbbVie closed Friday up 7c to $87.48.
09/25/17
JEFF
09/25/17
NO CHANGE
Target $200
JEFF
Buy
Jefferies explains how Amgen can re-rate higher like AbbVie
Jefferies analyst Michael Yee believes the 2018-2020 consensus estimates for Amgen (AMGN) may be too low if Mylan's (MYL) biosimilar of Neulasta doesn't get approved next month. The Biosimilar User Fee Act date is October 9. Investors may become more confident in the durability of Amgen's franchise given that AbbVie (ABBV) defended Humira and re-rated to a higher valuation, Yee tells investors in a research note. The key issue keeping Amgen's price-to-earnings multiple below peers at 12 to 13 times over the past couple of years is investor fear of biosimilars primarily against Neulasta and Enbrel, Yee argues. He sees a failed approval for Mylan as setting the tone for a higher multiple like AbbVie. The analyst has a Buy rating on Amgen shares with a $200 price target.
09/25/17
09/25/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UAA) downgraded to Neutral from Buy at Guggenheim. 2. VF Corp. (VFC) downgraded to Sector Weight from Overweight at KeyBanc with analyst Edward Yruma saying the company's "consistent" results are adequately reflected in the current valuation. 3. Quest Diagnostics (DGX) downgraded to Market Perform from Outperform at Raymond James with analyst Nicholas Jansen citing the preliminary 2018 Clinical Laboratory Fee Schedule, or CLFS, rates released Friday evening, which creates an overhang. 4. AbbVie (ABBV) downgraded to Neutral from Buy at UBS with analyst Marc Goodman saying that shares are up 40% year-to-date. 5. Albemarle (ALB) downgraded to Neutral from Outperform at Baird with analyst Ben Kallo saying he thinks near-term execution is largely priced into the stock and he believes the shares are fully valued at current levels. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/27/17
FBCO
09/27/17
NO CHANGE
Target $17
FBCO
Outperform
Coherus Biosciences price target lowered to $17 from $24 at Credit Suisse
Credit Suisse analyst Alethia Young lowered her price target for Coherus Biosciences (CHRS) to $17 from $24 as she is pushing her worldwide launch timeline assumption to 2022 from 2020 for the biosimilar Humira from AbbVie (ABBV). The analyst reiterates an Outperform rating on Coherus Biosciences shares.
AMGN Amgen
$184.88

-0.72 (-0.39%)

09/07/17
PIPR
09/07/17
NO CHANGE
Target $557
PIPR
Overweight
Regeneron selloff today a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes shares of Regeneron Pharmaceuticals (REGN) are trading lower after Phase IIb readouts from competitors Amgen (AMGN) and AstraZeneca (AZN) in asthma and AbbVie (ABBV) in atopic dermatitis met their primary endpoints. The analyst does not see an "immediate competitive threat" to Regeneron's Dupixent, which he says has successfully launched in atopic dermatitis following FDA approval in March. He recommends buying the shares on today's selloff ahead of expected "positive" Phase III Dupixent asthma data. Dupixent maintains at least a two-year lead ahead of these competitive agents, Tenthoff tells investors in an intraday research note. The analyst reiterates an Overweight rating on Regeneron with a $557 price target.
09/14/17
RBCM
09/14/17
INITIATION
Target $192
RBCM
Sector Perform
Amgen initiated with a Sector Perform at RBC Capital
RBC Capital analyst Kennen MacKay initiated Amgen with a Sector Perform and an $192 price target.
09/21/17
UBSW
09/21/17
NO CHANGE
Target $500
UBSW
Buy
Regeneron price target lowered to $500 from $535 at UBS
UBS analyst Carter Gould lowered his price target on Regeneron (REGN) to $500 from $535 citing increased Dupixent competition after Amgen (AMGN) and AstraZeneca (AZN) reported data on their own asthma drug earlier this month and AbbVie (ABBV) reported results in an atopic dermatitis study. While he noted that definitive 12-month phase 3 data from these competitors is likely more than 20 months away, he also lowered his Dupixent peak sales estimate to $4.8B from $6.5B. He keeps a Buy rating on Regeneron shares, as he believes pipeline products including nesvacumab and REGN2810 offer a path to longer-term upside.

TODAY'S FREE FLY STORIES

OMER

Omeros

$11.37

0.36 (3.27%)

10:14
02/21/18
02/21
10:14
02/21/18
10:14
Periodicals
Symphony data show Omidria sales fell 87% in January, Four World says »

Short seller Four World…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COLL

Collegium Pharmaceutical

$25.70

-0.2 (-0.77%)

10:12
02/21/18
02/21
10:12
02/21/18
10:12
Hot Stocks
FDA says Collegium made false or misleading claims about Xtampza »

The FDA posted a letter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 01

    Mar

VECO

Veeco

$18.35

-0.55 (-2.91%)

10:11
02/21/18
02/21
10:11
02/21/18
10:11
Conference/Events
Veeco management to meet with KeyBanc »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

CLF

Cleveland-Cliffs

$7.62

-0.12 (-1.55%)

10:10
02/21/18
02/21
10:10
02/21/18
10:10
Options
Bearish option flow in Cleveland Cliffs »

Bearish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:10
02/21/18
02/21
10:10
02/21/18
10:10
General news
U.S. existing home sales preview: »

U.S. existing home sales…

MTCH

Match Group

$42.10

0.54 (1.30%)

, IAC

IAC

$149.83

0.74 (0.50%)

10:09
02/21/18
02/21
10:09
02/21/18
10:09
Hot Stocks
Match Group slips after analyst cuts rating on Tinder slowdown »

Shares of Match Group…

MTCH

Match Group

$42.10

0.54 (1.30%)

IAC

IAC

$149.83

0.74 (0.50%)

ANGI

Angi Homeservices

$14.60

0.58 (4.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

MOS

Mosaic

$27.78

1.0176 (3.80%)

10:05
02/21/18
02/21
10:05
02/21/18
10:05
Options
Mosaic call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 28

    Feb

10:05
02/21/18
02/21
10:05
02/21/18
10:05
General news
More from Harker: a trade war would not be good »

More from Harker: a trade…

ABBV

AbbVie

$120.00

2.02 (1.71%)

10:05
02/21/18
02/21
10:05
02/21/18
10:05
Recommendations
AbbVie analyst commentary  »

Piper says 'hard to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

10:04
02/21/18
02/21
10:04
02/21/18
10:04
General news
Existing Home Sales data reported »

January Existing Home…

RDWR

Radware

$21.09

-0.25 (-1.17%)

10:04
02/21/18
02/21
10:04
02/21/18
10:04
Conference/Events
Radware management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 29

    Mar

RDWR

Radware

$21.09

-0.25 (-1.17%)

10:01
02/21/18
02/21
10:01
02/21/18
10:01
Conference/Events
Radware management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 29

    Mar

QTWO

Q2 Holdings

$42.85

-1.8 (-4.03%)

10:00
02/21/18
02/21
10:00
02/21/18
10:00
Conference/Events
Q2 Holdings management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 15

    Mar

10:00
02/21/18
02/21
10:00
02/21/18
10:00
General news
U.S. Markit manufacturing PMI rose 0.4 points to 55.9 in the flash February »

U.S. Markit manufacturing…

LFUS

Littelfuse

$208.66

0.61 (0.29%)

09:59
02/21/18
02/21
09:59
02/21/18
09:59
Conference/Events
Littelfuse management to meet with Oppenheimer »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

NJDCY

Nidec

$37.80

-0.12 (-0.32%)

09:57
02/21/18
02/21
09:57
02/21/18
09:57
Conference/Events
Nidec management to meet with Oppenheimer »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

HDP

Hortonworks

$18.22

0.03 (0.16%)

09:55
02/21/18
02/21
09:55
02/21/18
09:55
Conference/Events
Hortonworks management to meet with Northland »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

  • 26

    Feb

  • 11

    Mar

  • 13

    Mar

  • 14

    Mar

  • 11

    Apr

  • 30

    May

PVG

Pretium Resources

$6.56

-0.05 (-0.76%)

09:55
02/21/18
02/21
09:55
02/21/18
09:55
Options
Pretium Resources put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Mar

  • 11

    Mar

AAP

Advance Auto Parts

$115.88

10.53 (10.00%)

, EXR

Extra Space Storage

$84.86

4.105 (5.08%)

09:55
02/21/18
02/21
09:55
02/21/18
09:55
Options
Early notable gainers among liquid option names on February 21st »

Notable gainers among…

AAP

Advance Auto Parts

$115.88

10.53 (10.00%)

EXR

Extra Space Storage

$84.86

4.105 (5.08%)

MOS

Mosaic

$27.48

0.72 (2.69%)

CF

CF Industries

$42.80

0.975 (2.33%)

VRSK

Verisk Analytics

$97.04

-1.75 (-1.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 25

    Feb

  • 25

    Feb

  • 28

    Feb

  • 30

    May

GVA

Granite Construction

$60.01

0.0066 (0.01%)

09:52
02/21/18
02/21
09:52
02/21/18
09:52
Conference/Events
Granite Construction management to meet with MKM Partners »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 23

    May

CPS

Cooper-Standard

$120.74

-0.8988 (-0.74%)

09:51
02/21/18
02/21
09:51
02/21/18
09:51
Conference/Events
Cooper-Standard management to meet with Roth Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 11

    Mar

LEXEB

Liberty Expedia Holdings

09:50
02/21/18
02/21
09:50
02/21/18
09:50
Hot Stocks
Breaking Hot Stocks news story on Liberty Expedia Holdings  »

Liberty Expedia Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANET

Arista Networks

$249.53

-0.125 (-0.05%)

09:50
02/21/18
02/21
09:50
02/21/18
09:50
Conference/Events
Arista Networks management to meet with KeyBanc »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

  • 26

    Feb

  • 06

    Mar

  • 13

    Mar

  • 14

    Mar

  • 29

    Mar

LEXEB

Liberty Expedia Holdings

09:45
02/21/18
02/21
09:45
02/21/18
09:45
Hot Stocks
Breaking Hot Stocks news story on Liberty Expedia Holdings  »

Liberty Expedia Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:45
02/21/18
02/21
09:45
02/21/18
09:45
General news
Existing Home Sales to be reported at 10:00 »

January Existing Home…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.